CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast AsiaGlobeNewsWire • 04/01/24
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisBusiness Wire • 03/10/24
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaBusiness Wire • 03/10/24
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingBusiness Wire • 03/04/24
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AIBusiness Wire • 02/29/24
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host DiseaseBusiness Wire • 02/27/24
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesBusiness Wire • 02/13/24
Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks Investment Research • 02/09/24
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)Business Wire • 02/05/24